EndoChoice Holdings (NYSE: GI) and Analogic Corporation (NASDAQ:ALOG) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitabiliy, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for EndoChoice Holdings and Analogic Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EndoChoice Holdings 0 2 1 0 2.33
Analogic Corporation 0 2 1 0 2.33

EndoChoice Holdings currently has a consensus price target of $7.00, suggesting a potential downside of 12.50%. Analogic Corporation has a consensus price target of $91.00, suggesting a potential upside of 26.56%. Given Analogic Corporation’s higher possible upside, analysts plainly believe Analogic Corporation is more favorable than EndoChoice Holdings.

Volatility & Risk

EndoChoice Holdings has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Analogic Corporation has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Institutional & Insider Ownership

37.3% of EndoChoice Holdings shares are owned by institutional investors. 31.5% of EndoChoice Holdings shares are owned by insiders. Comparatively, 1.2% of Analogic Corporation shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Analogic Corporation pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. EndoChoice Holdings does not pay a dividend. Analogic Corporation pays out -12.2% of its earnings in the form of a dividend.


This table compares EndoChoice Holdings and Analogic Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EndoChoice Holdings -90.67% -130.29% -60.59%
Analogic Corporation -7.97% 6.75% 5.73%

Earnings and Valuation

This table compares EndoChoice Holdings and Analogic Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
EndoChoice Holdings N/A N/A N/A ($2.67) -3.00
Analogic Corporation $512.87 million 1.75 $65.24 million ($3.29) -21.85

Analogic Corporation has higher revenue and earnings than EndoChoice Holdings. Analogic Corporation is trading at a lower price-to-earnings ratio than EndoChoice Holdings, indicating that it is currently the more affordable of the two stocks.


Analogic Corporation beats EndoChoice Holdings on 7 of the 11 factors compared between the two stocks.

About EndoChoice Holdings

EndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company’s products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company’s imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company’s single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.

About Analogic Corporation

Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies. The Company operates through three segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography. The Company’s Ultrasound business segment provides ultrasound procedure guidance systems for the urology and surgery markets. The Company’s Security and Detection segment designs and manufactures automated threat detection systems for aviation baggage inspection applications utilizing medical CT technology and systems used for deoxyribonucleic acid (DNA) analysis for law enforcement and government agencies.

Receive News & Ratings for EndoChoice Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.